A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

Cancer
Jan SamuelssonNordic Study Group for Myeloproliferative Disorders

Abstract

Conventional interferon-alpha (IFN) is an effective treatment for patients with myeloproliferative disorders. However, many patients discontinue therapy because of side effects. In this 24-month, Phase II feasibility study of pegylated interferon alpha-2b (PEG-IFN) treatment, a starting dose of 0.5 microg/kg per week was received by 21 patients with polycythemia vera (PV) and 21 patients with essential thrombocythemia (ET). The treatment objective, a complete platelet response (CR), was a platelet count<400x10(9)/L in symptomatic patients and <600 in asymptomatic patients. Neutrophil polycythemia rubra vera-1 (PRV-1) messenger RNA expression was analyzed prior to and during therapy. Quality of life (QoL) was investigated by using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire. At 6 months, 29 of 42 patients (69%) had achieved a CR after a median of 83 days. The CR rate was not related to diagnosis, gender, or previous therapy. Nineteen patients completed the planned 2-year treatment in CR. No thromboembolic or bleeding complications were observed. Phlebotomy requirements were reduced in the majority of patients with PV. Five of 14 patients (36%) who initially were positive for PRV-1 achieve...Continue Reading

References

Mar 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S CortelazzoT Barbui
Jan 1, 1987·Cancer Immunology, Immunotherapy : CII·H LudwigM Micksche
Jun 1, 1983·Acta Psychiatrica Scandinavica·A S Zigmond, R P Snaith
Apr 27, 1995·The New England Journal of Medicine·S CortelazzoT Barbui
Feb 1, 1994·British Journal of Haematology·C MessoraS Sacchi
Sep 1, 1996·Leukemia & Lymphoma·E LengfelderR Hehlmann
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D OsobaJ Pater
May 10, 2000·Annals of Hematology·E LengfelderR Hehlmann
Dec 24, 2002·Cancer Chemotherapy and Pharmacology·Yesid AlvaradoFrancis J Giles
Jun 4, 2004·Annals of Hematology·Francesco PassamontiMario Lazzarino
Oct 16, 2004·Clinical and Laboratory Haematology·E PenningaH C Hasselbalch
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roberto MarchioliTiziano Barbui
Mar 10, 2005·Leukemia Research·Steven M FruchtmanUNKNOWN Anagrelide Study Group
Jul 8, 2005·The New England Journal of Medicine·Claire N HarrisonUNKNOWN United Kingdom Medical Research Council Primary Thrombocythemia 1 Study

❮ Previous
Next ❯

Citations

Jul 17, 2008·Annals of Hematology·Gunnar Birgegård
Apr 11, 2013·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Brady L Stein, Ramon V Tiu
Sep 28, 2007·Current Opinion in Hematology·David F Stroncek
Jan 11, 2007·Orphanet Journal of Rare Diseases·Jean B Brière
Dec 2, 2006·Drugs·Elisabeth I Penninga, Ole W Bjerrum
Feb 5, 2013·Expert Review of Hematology·Richard T SilverHans Carl Hasselbalch
May 23, 2015·Expert Review of Hematology·Hans Carl Hasselbalch, Richard T Silver
May 15, 2013·Expert Opinion on Pharmacotherapy·Gunnar Birgegård
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Naseema Gangat, Ayalew Tefferi
Feb 19, 2013·Cytokine & Growth Factor Reviews·Hans C Hasselbalch
Feb 12, 2009·American Journal of Hematology·Francesca PalandriNicola Vianelli
Aug 25, 2015·Clinical Lymphoma, Myeloma & Leukemia·Lorenzo FalchiSrdan Verstovsek
Mar 14, 2013·Expert Opinion on Pharmacotherapy·Benjamin HensleyRuben Mesa
Jul 13, 2016·Critical Reviews in Oncology/hematology·Aziz NazhaNaval Daver
Nov 28, 2012·Medicina clínica·Gemma RamirezSylvia Plaza
Sep 2, 2016·Expert Review of Hematology·Sachin Gopalkrishna PaiFrancis Joseph Giles
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans Carl HasselbalchRichard T Silver
Jul 3, 2015·Therapeutic Advances in Hematology·Gunnar Birgegård
Nov 28, 2018·British Journal of Haematology·Mary Frances McMullinUNKNOWN BSH Committee
May 6, 2020·Expert Opinion on Therapeutic Targets·Niccolò BartalucciAlessandro M Vannucchi
Jun 4, 2020·International Journal of Molecular Sciences·Alessandra MalatoNovella Pugliese

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.